BARUCH S BLUMBERG INST has a total of 47 patent applications. It decreased the IP activity by 62.0%. Its first patent ever was published in 2012. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and biotechnology are NIKANG THERAPEUTICS INC, TAVARES FRANCIS XAVIER and TOYAMA CHEMICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | Australia | 7 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Japan | 5 | |
#5 | Brazil | 4 | |
#6 | WIPO (World Intellectual Property Organization) | 4 | |
#7 | China | 3 | |
#8 | New Zealand | 3 | |
#9 | Singapore | 2 | |
#10 | Canada | 1 | |
#11 | Israel | 1 | |
#12 | Philippines | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Biotechnology | |
#4 | Measurement | |
#5 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Block Timothy M | 29 |
#2 | Xu Xiaodong | 29 |
#3 | Guo Ju-Tao | 27 |
#4 | Du Yanming | 20 |
#5 | Cuconati Andrea | 15 |
#6 | Lu Huagang | 12 |
#7 | Guo Haitao | 8 |
#8 | Timothy M Block | 8 |
#9 | Cai Dawei | 8 |
#10 | Chang Jinhong | 7 |
Publication | Filing date | Title |
---|---|---|
WO2020072492A1 | Benzamide derivatives as cgas-sting pathway agonists | |
US2019241552A1 | Substituted aminothiazoles | |
US2017305856A1 | 2,3-diacylated, 2- and 3-mono-acylated alkylated imino sugars exhibiting glucosidase inhibition and their method of use | |
US2016327571A1 | Lectin Assay For Assessing Glycoforms As An Early Marker In Disease | |
WO2015191179A1 | Ttp inhibitiors of low density lipprotein secretion for the management of diseases associated with elevated blood ldl levels | |
NZ708392A | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
US2015119366A1 | Alkylated imino sugars exhibiting glucosidase inhibition and their method of use | |
AU2012318670A1 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |